Table 2.

Five-year OS rates (95% CI) and AHRs (95% CI) for individual VDR polymorphism

GenotypesAll patients
Adenocarcinoma
SCC
nDeath5-year survivalAHRnDeath5-year survivalAHRnDeath5-year survivalAHR
VDR Cdx-2 G>A polymorphism
    G/G20110554% (47-61%)1.00873964% (53-74%)1.00664441% (28-53%)1.00
    G/A1446958% (50-67%)0.84 (0.62-1.14)783962% (51-74%)1.02 (0.64-1.62)371955% (38-72%)0.55 (0.32-0.95)
    A/A281253% (33-73%)0.92 (0.50-1.68)15947% (21-72%)1.71 (0.81-3.60)5260% (17-100%)0.69 (0.16-2.96)
    P*0.400.370.570.330.120.05
    G/A+A/A1728159% (51-67%)0.85 (0.63-1.14)934860% (50-70%)1.11 (0.72-1.73)422155% (39-71%)0.56 (0.33-0.95)
VDR FokI C>T polymorphism
    C/C1417654% (45-63%)1.00683062% (50-75%)1.00443040% (24-56%)1.00
    C/T1707959% (52-67%)0.84 (0.61-1.16)784159% (47-70%)1.13 (0.67-1.88)482552% (37-66%)0.75 (0.44-1.28)
    T/T623155% (42-68%)1.13 (0.74-1.74)341662% (45-79%)1.31 (0.70-2.46)161045% (19-71%)0.98 (0.47-2.03)
    P*0.470.930.750.400.490.64
VDR BsmI C>T polymorphism
    C/C1196152% (42-62%)1.00542559% (45-73%)1.00332238% (21-55%)1.00
    C/T1828964% (57-72%)0.83 (0.59-1.16)924467% (57-77%)0.88 (0.52-1.48)502659% (44-74%)0.59 (0.33-1.05)
    T/T724044% (32-56%)1.35 (0.90-2.03)341847% (29-66%)1.52 (0.81-2.83)251731% (11-51%)1.18 (0.62-2.23)
    P*0.200.310.630.300.080.83
  • NOTE: AHRs, adjusting for age, gender, smoking status, stage, and surgery season, where appropriate.

  • * The Ps were for log-rank test or trend test in Cox proportional hazards models, respectively.